School of Medicine, Stony Brook University Medical Center, Stony Brook, NY 11794, USA.
Pediatr Nephrol. 2010 Apr;25(4):725-32. doi: 10.1007/s00467-009-1409-1. Epub 2009 Dec 24.
Dramatic changes have occurred in our understanding of the etiology of the growth retardation associated with chronic kidney disease (CKD) and end-stage renal disease (ESRD) during the past 50 years. Significant interest has been focused on preventing and/or correcting the growth retardation because of the emergence of the dual therapeutic modalities of dialysis and renal transplantation to prolong the lives of infants, children, and adolescents afflicted with CKD and ESRD. These efforts have resulted in a significant improvement in the height Z-score over the past two decades of children with CKD and ESRD. This has had a salutary impact on the final adult height of such children which should hopefully lead to an enhanced quality of life in the future. This report addresses the progress that has been made in the management of growth retardation in the pediatric population with CKD and ESRD.
在过去的 50 年中，我们对慢性肾脏病（CKD）和终末期肾病（ESRD）相关生长迟缓的病因有了深刻的认识。由于透析和肾移植这两种治疗方法的出现，使患有 CKD 和 ESRD 的婴儿、儿童和青少年的生命得以延长，因此人们对预防和/或纠正生长迟缓产生了浓厚的兴趣。这些努力使过去二十年患有 CKD 和 ESRD 的儿童的身高 Z 评分有了显著提高。这对这些儿童的最终成年身高产生了有益的影响，有望在未来提高他们的生活质量。本报告讨论了在 CKD 和 ESRD 儿科人群中管理生长迟缓方面取得的进展。
